Abstract
The mortality and morbidity rates for prostate cancer have recently increased to alarming levels, rising higher than lung cancer. Due to a lack of drug targets and molecular probes, existing theranostic techniques are limited. Human LIN28A and its paralog LIN28B overexpression are associated with a number of tumors resulting in a remarkable increase in cancer aggression and poor prognoses. The current review aims to highlight recent work identifying the key roles of LIN28A and LIN28B in prostate cancer, and to instigate further preclinical and clinical research in this important area.
| Original language | English |
|---|---|
| Pages (from-to) | 3873-3880 |
| Number of pages | 8 |
| Journal | Future Oncology |
| Volume | 17 |
| Issue number | 29 |
| Early online date | 15 Jul 2021 |
| DOIs | |
| Publication status | Published (in print/issue) - 31 Oct 2021 |
Bibliographical note
Publisher Copyright:© 2021 Future Medicine Ltd.. All rights reserved.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cancer
- theranostic
- Therapeutic
- LIN28B
- prostate cancer
- LIN28A
- Special Report
- biomarker
- Humans
- Male
- Molecular Targeted Therapy
- RNA-Binding Proteins/metabolism
- Prostatic Neoplasms/pathology
- Precision Medicine
Fingerprint
Dive into the research topics of 'Targeting LIN28: a new hope in prostate cancer theranostics'. Together they form a unique fingerprint.Student theses
-
Molecular analysis of the effects of crocin on acute myeloid leukaemia, pancreatic and colon cancer
Bakshi, H. A. (Author), Mc Carron, P. (Supervisor), Webba Da Silva, M. (Supervisor) & Tambuwala, M. (Supervisor), Aug 2022Student thesis: Doctoral Thesis
File
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver